MiNK-101

About MiNK Therapeutics

MiNK Therapeutics is advancing a first-in-class, allogeneic iNKT cell therapy platform with the mission to deliver effective, readily available 'living medicines' for oncology and inflammatory diseases. The company has demonstrated initial clinical proof-of-concept, having treated over 70 patients across its programs in solid tumors and ARDS, and is leveraging the inherent safety and versatility of iNKT cells to build a pipeline of off-the-shelf products. Its strategy focuses on validating its lead assets, expanding into new indications through strategic combinations, and pioneering next-generation engineered iNKT cells to enhance targeting and persistence.

Therapeutic Areas

Other Relapsed/Refractory Solid Tumors Drugs